Td Asset Management Inc Immuno Gen, Inc. Transaction History

Td Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$14.09 - $19.87 $2.6 Million - $3.67 Million	184,500 Added 188.46%	282,400 $4.48 Million
Q2 2023 Aug 09, 2023	BUY	$3.75 - $20.05 $367,125 - $1.96 Million	97,900 New	97,900 $1.85 Million
Q4 2019 Feb 11, 2020	SELL	$2.25 - $5.8 $30,674 - $79,071	-13,633 Closed	0 $0
Q2 2019 Aug 01, 2019	SELL	$1.8 - $3.3 $83,372 - $152,849	-46,318 Reduced 77.26%	13,633 $30,000
Q1 2019 May 08, 2019	SELL	$2.41 - $5.91 $9,355 - $22,942	-3,882 Reduced 6.08%	59,951 $162,000
Q3 2018 Nov 01, 2018	SELL	$8.6 - $11.26 $73,100 - $95,710	-8,500 Reduced 11.75%	63,833 $604,000
Q2 2018 Jul 31, 2018	BUY	$9.52 - $12.15 $159,298 - $203,305	16,733 Added 30.1%	72,333 $704,000
Q1 2018 May 11, 2018	BUY	$6.7 - $12.95 $46,230 - $89,355	6,900 Added 14.17%	55,600 $585,000
Q4 2017 Feb 02, 2018	BUY	$5.07 - $7.92 $57,291 - $89,496	11,300 Added 30.21%	48,700 $312,000
Q3 2017 Nov 09, 2017	BUY	$5.4 - $8.47 $201,960 - $316,778	37,400	37,400 $286,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.